BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T12:00:12+00:00 May 15th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2012

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T12:01:45+00:00 May 15th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By | 2016-02-07T15:48:27+00:00 May 15th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2012

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By | 2016-02-07T15:49:19+00:00 May 15th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Amendment No. 1 to the Employment Agreement th This Amendment No. 1 (the “Amendment”) to Employment Agreement is made as of this 20 WITNESSETH WHEREAS WHEREAS WHEREAS NOW THEREFORE 2. Term 1. Paragraph 2. Term “ 2. In all other respects, the provisions of the Employment Agreement as restated remain unchanged and in full force and effect. 3. This Amendment]

By | 2016-03-03T12:02:57+00:00 April 24th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Amendment No. 1 to the Employment Agreement th

[Amendment No. 1 to the Employment Agreement th This Amendment No. 1 (the “Amendment”) to Employment Agreement is made as of this 20 WITNESSETH WHEREAS WHEREAS WHEREAS NOW THEREFORE 2. Term 1. Paragraph 2. Term “ 2. In all other respects, the provisions of the Employment Agreement as restated remain unchanged and in full force and effect. 3. This Amendment]

By | 2016-03-03T12:04:27+00:00 April 24th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Amendment No. 1 to the Employmentreement th This Amendment No. 1 (the Amendment) to Employmentreement is made of this 20 WITNESSETH WHEREAS WHEREAS WHEREAS NOW THEREFORE 2. Term 1.Paragraph 2.Inl other respects, the provisions of the Employmentreement restated remain unchanged and in full force and effect.]

By | 2016-02-07T15:50:16+00:00 April 24th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Amendment No. 1 to the Employmentreement th This

[Amendment No. 1 to the Employmentreement th This Amendment No. 1 (the Amendment) to Employmentreement is made of this 20 WITNESSETH WHEREAS WHEREAS WHEREAS NOW THEREFORE 2. Term 1.Paragraph 2.Inl other respects, the provisions of the Employmentreement restated remain unchanged and in full force and effect.]

By | 2016-02-07T15:51:12+00:00 April 24th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]

By | 2016-03-03T12:06:04+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION

[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]

By | 2016-03-03T12:08:17+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar